Ofatumumab in AQP4-IgG Seropositive NMOSD
Ofatumumab in AQP4-IgG Seropositive NMOSD
Recruiting · NCT05504694 · Registry updated 2026-01-30Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Ofatumumab in AQP4-IgG Seropositive NMOSD | CNS demyelinating autoimmune disease, acute transverse myelitis, autoimmune disease, autoimmune disorder of the nervous system, cranial nerve neuropathy, demyelinating disease, eye disorder, immune system disorder, nervous system disorder, neuromyelitis optica, optic nerve disorder, optic neuritis | Recruiting | Phase 1 / Phase 2 | 2026-01-30 | NCT05504694 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Henan Provincial People's Hospital | 95 |
| Tang-Du Hospital | 93 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Tangdu Hospital | Xi'an | China | 5 |